ALTTO | ESMO Open

ALTTO | ESMO Open

OVERVIEW Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. The final 10-year analysis of the ALTTO trial is presented here. study details The Adjuvant...
APHINITY | Journal of Clinical Oncology

APHINITY | Journal of Clinical Oncology

OVERVIEW The human epidermal growth factor receptor 2 (HER2) is the second most important target for systemic breast cancer (BC) therapy after the estrogen receptor. HER2 overexpression is found in 15%-20% of patients with BC. Today, HER2-directed therapies are...